CooperSurgical Inc.’s video promotion for its intrauterine copper contraceptive Paragard was particularly problematic for the US Food and Drug Administration, as it excluded any risk information, raised public health concerns, and was a repeat violation.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?